Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. EBT Margin for the year ending December 31, 2023: 20.45%

Jiangsu Hengrui Medicine Co., Ltd. EBT Margin is 20.45% for the year ending December 31, 2023, a 9.64% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Jiangsu Hengrui Medicine Co., Ltd. EBT Margin for the year ending December 31, 2022 was 18.65%, a 8.19% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBT Margin for the year ending December 31, 2021 was 17.24%, a -30.66% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBT Margin for the year ending December 31, 2020 was 24.86%, a -4.39% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. EBT Margin for the year ending December 31, 2019 was 26.00%, a 0.67% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years